{
  "$schema": "https://themachinepress.com/schemas/story-v1.schema.json",
  "schema_version": "1.0.0",
  "document_type": "machine_press_story",
  "story": {
    "story_id": "mp-2026-08-01-027",
    "source_story_id": "tmp-story-opti-dor-hiv-trial",
    "edition_id": "mp-2026-08-01-morning-0023",
    "edition_url": "https://themachinepress.com/edition/2026-08-01",
    "position": 16,
    "story_type": "dispatch",
    "section": "research",
    "editorial_classification": "editorial",
    "headline": "An HIV Regimen Matched Suppression With Less Weight Gain",
    "slug": "an-hiv-regimen-matched-suppression-with-less-weight-gain",
    "dek": "A South African comparison found doravirine noninferior to dolutegravir while producing more favorable weight and lipid outcomes.",
    "summary": "A South African comparison found doravirine noninferior to dolutegravir while producing more favorable weight and lipid outcomes.",
    "body_text": "The Opti-DOR trial in rural KwaZulu-Natal and urban Gauteng compared tenofovir-lamivudine-doravirine with the country's standard tenofovir-lamivudine-dolutegravir regimen. Researchers report that doravirine was noninferior for viral suppression and was associated with less weight gain and better lipid measures. The result offers another treatment option; individual prescribing still depends on clinical guidance and access.",
    "why_it_matters": "A South African comparison found doravirine noninferior to dolutegravir while producing more favorable weight and lipid outcomes.",
    "limitations": [],
    "importance": 9,
    "canonical_url": "https://themachinepress.com/story/mp-2026-08-01-027/an-hiv-regimen-matched-suppression-with-less-weight-gain",
    "json_url": "https://themachinepress.com/story/mp-2026-08-01-027.json",
    "first_published_at": "2026-08-01T09:00:00.000-04:00",
    "modified_at": "2026-08-01T09:00:00.000-04:00",
    "content_status": "new",
    "is_carryover": false,
    "carryover_reason": null,
    "key_claims": [
      {
        "claim_id": "claim-mp-2026-08-01-027-001",
        "text": "A South African comparison found doravirine noninferior to dolutegravir while producing more favorable weight and lipid outcomes.",
        "source_ids": [
          "source-2026-08-01-016"
        ],
        "qualification": null
      }
    ],
    "source_ids": [
      "source-2026-08-01-016"
    ],
    "tags": [
      "HIV",
      "doravirine",
      "dolutegravir",
      "South Africa"
    ],
    "image_url": null,
    "corrections": []
  },
  "sources": [
    {
      "source_id": "source-2026-08-01-016",
      "title": "Wits University via Newswise: Opti-DOR HIV trial",
      "publisher": "University of the Witwatersrand via Newswise",
      "url": "https://www.newswise.com/articles/another-hiv-treatment-option-but-with-less-weight-gain",
      "canonical_url": "https://www.newswise.com/articles/another-hiv-treatment-option-but-with-less-weight-gain",
      "source_type": "official_announcement",
      "is_primary_source": true,
      "published_at": null,
      "accessed_at": "2026-08-01T08:36:00.000-04:00",
      "supports_claim_ids": [
        "claim-mp-2026-08-01-027-001"
      ]
    }
  ],
  "corrections": [],
  "publisher": {
    "name": "The Machine Press",
    "url": "https://themachinepress.com",
    "description": "A daily newspaper for the age of artificial intelligence."
  },
  "cite_this_report": {
    "title": "An HIV Regimen Matched Suppression With Less Weight Gain",
    "publisher": "The Machine Press",
    "published_at": "2026-08-01T09:00:00.000-04:00",
    "canonical_url": "https://themachinepress.com/story/mp-2026-08-01-027/an-hiv-regimen-matched-suppression-with-less-weight-gain"
  }
}